Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report.

Literature DB >> 19652960

Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report.

Srecko Marusic, Nives Gojo-Tomic, Miljenko Franic, Nada Bozina.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19652960 DOI： 10.1007/s00228-009-0710-z

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

× No keyword cloud information.

15 in total

1. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.

Authors: Ronen Loebstein; Ilana Dvoskin; Hillel Halkin; Manuela Vecsler; Aharon Lubetsky; Gideon Rechavi; Ninette Amariglio; Yoram Cohen; Gie Ken-Dror; Shlomo Almog; Eva Gak
Journal: Blood Date: 2006-11-16 Impact factor: 22.113

Review 2. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors: Mike Ufer
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

3. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

Authors: Tom Schalekamp; Bjorn P Brassé; Janine F M Roijers; Youssef Chahid; Johanna H H van Geest-Daalderop; Hanneke de Vries-Goldschmeding; Eduard M van Wijk; Antoine C G Egberts; Anthonius de Boer
Journal: Clin Pharmacol Ther Date: 2006-07 Impact factor: 6.875

4. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.

Authors: H H Thijssen; J P Flinois; P H Beaune
Journal: Drug Metab Dispos Date: 2000-11 Impact factor: 3.922

5. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.

Authors: R B Saraeva; I D Paskaleva; E Doncheva; C B Eap; V S Ganev
Journal: J Clin Pharm Ther Date: 2007-12 Impact factor: 2.512

6. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors: Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal: Nature Date: 2004-02-05 Impact factor: 49.962

Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report.

1. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.

Review 2. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

3. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

4. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.

5. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.

6. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Review 7. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.

Review 8. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.

Review 9. VKORC1: molecular target of coumarins.

10. Novel mutations in the VKORC1 gene of wild rats and mice--a response to 50 years of selection pressure by warfarin?

Review 1. Oral Anticoagulant Therapy-When Art Meets Science.